MX343273B - Intermediarios clave para la sintesis de rosuvastatina o de sales farmaceuticamente aceptables de la misma. - Google Patents

Intermediarios clave para la sintesis de rosuvastatina o de sales farmaceuticamente aceptables de la misma.

Info

Publication number
MX343273B
MX343273B MX2011007990A MX2011007990A MX343273B MX 343273 B MX343273 B MX 343273B MX 2011007990 A MX2011007990 A MX 2011007990A MX 2011007990 A MX2011007990 A MX 2011007990A MX 343273 B MX343273 B MX 343273B
Authority
MX
Mexico
Prior art keywords
rosuvastatin
synthesis
pharmaceutically acceptable
acceptable salts
key intermediates
Prior art date
Application number
MX2011007990A
Other languages
English (en)
Other versions
MX2011007990A (es
Inventor
Casar Zdenko
Kosmrlj Janez
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of MX2011007990A publication Critical patent/MX2011007990A/es
Publication of MX343273B publication Critical patent/MX343273B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/535—Organo-phosphoranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere en general al campo de la química orgánica, y en particular a la preparación de la N-(4-(4-fluoro-fenil)-6-isopropil-5-metil-pirimidin-2-il)-N-metil -metan-sulfonamida (I), de la N-(4-(4-fluoro-fenil)-5-(bromo-metil )-6-iso-propil-pirimidin-2-il)-N-metil-metan-sulfonamida (II), y de la N-(4-(4-fIuoro-fenil)-5-(hidroxi-metil)-6-isopropil-pirimidi n-2-il)-N-metil-metan-sulfonamida (III), como los intermediarios clave en la preparación de la rosuvastatina.
MX2011007990A 2009-02-02 2010-02-01 Intermediarios clave para la sintesis de rosuvastatina o de sales farmaceuticamente aceptables de la misma. MX343273B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09151881A EP2264015A1 (en) 2009-02-02 2009-02-02 Key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
PCT/EP2010/051163 WO2010086438A1 (en) 2009-02-02 2010-02-01 Key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof

Publications (2)

Publication Number Publication Date
MX2011007990A MX2011007990A (es) 2011-09-06
MX343273B true MX343273B (es) 2016-10-31

Family

ID=40589996

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007990A MX343273B (es) 2009-02-02 2010-02-01 Intermediarios clave para la sintesis de rosuvastatina o de sales farmaceuticamente aceptables de la misma.

Country Status (10)

Country Link
US (2) US20120022091A1 (es)
EP (2) EP2264015A1 (es)
JP (1) JP5558492B2 (es)
CN (1) CN102365272B (es)
AU (1) AU2010209650B2 (es)
BR (1) BRPI1007151A2 (es)
CA (1) CA2750801C (es)
EA (1) EA021733B1 (es)
MX (1) MX343273B (es)
WO (1) WO2010086438A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2423195A1 (en) * 2010-07-26 2012-02-29 LEK Pharmaceuticals d.d. Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof
SI2665722T1 (sl) 2011-01-18 2016-12-30 Dsm Sinochem Pharmaceuticals Netherlands B.V. Postopek priprave diol sulfonov
CN102311457B (zh) * 2011-09-16 2014-04-16 苏州莱克施德药业有限公司 罗苏伐他汀的制备方法
CN102936225A (zh) * 2012-11-15 2013-02-20 江苏阿尔法药业有限公司 一种含溴甲基、羟甲基或甲酰基的瑞舒伐他汀钙中间体的制备方法
CN103420919B (zh) * 2013-08-22 2015-07-08 南京欧信医药技术有限公司 一种嘧啶类衍生物的合成方法
CN105175346B (zh) * 2015-05-19 2018-02-06 上海弈柯莱生物医药科技有限公司 一种合成瑞舒伐他汀钙中间体的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO2005054207A1 (en) * 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
US8354530B2 (en) 2005-07-28 2013-01-15 Lek Pharmaceuticals d. d Process for the synthesis of rosuvastatin calcium
EP1775299A1 (en) * 2005-10-05 2007-04-18 LEK Pharmaceuticals D.D. Process for the synthesis of HMG-CoA reductase inhibitors
WO2008059519A2 (en) 2006-09-25 2008-05-22 Glenmark Pharmaceuticals Limited A process for the preparation of intermediates of rosuvastatin
EP2134696B1 (en) * 2007-04-03 2017-05-17 LEK Pharmaceuticals d.d. Processes for the preparation of statins, particularly rosuvastatin, and intermediates for the preparation thereof

Also Published As

Publication number Publication date
US20120022091A1 (en) 2012-01-26
JP5558492B2 (ja) 2014-07-23
AU2010209650A1 (en) 2011-08-25
EP2391609A1 (en) 2011-12-07
AU2010209650B2 (en) 2015-09-17
EA021733B1 (ru) 2015-08-31
JP2012516839A (ja) 2012-07-26
EA201101150A1 (ru) 2012-03-30
US9376397B2 (en) 2016-06-28
US20150141449A1 (en) 2015-05-21
WO2010086438A1 (en) 2010-08-05
MX2011007990A (es) 2011-09-06
CA2750801C (en) 2017-08-29
BRPI1007151A2 (pt) 2016-02-23
CA2750801A1 (en) 2010-08-05
EP2391609B1 (en) 2015-01-28
CN102365272B (zh) 2014-07-16
CN102365272A (zh) 2012-02-29
EP2264015A1 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
MX367795B (es) Inhibidores de cdk.
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
IL220155B (en) History of 2, 4-(phenyl-amine-)di-converted pyrimidines for use as kinase inhibitors
CY1121248T1 (el) Πολυμορφικες μορφες κι αλατα 6-(1h-ινδολ-4-υλ)-4-(5-{[4-(1-μεθυλαιθυλο)-1-πιπεραζινυλ]μεθυλο}-1,3-οξαζολ-2-υλ)-1η-ινδαζολιου ως αναστολεις ρi3κ για χρηση στη θεραπεια π.χ. αναπνευστικων διαταραχων
EA201200565A1 (ru) ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
MY157017A (en) Sulfonamide derivatives
UA108087C2 (uk) Тверді форми n-(4-(7-азабіцикло[2.2.1]гептан-7-іл)-2-(трифторметил)феніл)-4-оксо-5-(трифторметил)-1,4-дигідрохінолін-3-карбоксаміду
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
MX2011007990A (es) Intermediarios clave para la sintesis de rosuvastatina o de sales farmaceuticamente aceptables de la misma.
NZ700778A (en) Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{ 6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl} -1-methyl-urea and salts thereof.
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MX2012004114A (es) Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
EA201101186A1 (ru) Конденсированные пиримидины
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
MY170922A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
EA202091324A1 (ru) Комбинация 4-пиримидинсульфамидного производного с ингибитором sglt-2 для лечения заболеваний, связанных с эндотелином
UA107784C2 (en) Inhibitor of melanin production
ATE557023T1 (de) Piperidinylverbindungen als gpcr-agonisten
NZ599513A (en) Compounds for the treatment of dyslipidemia and related diseases
EA201270280A1 (ru) Соединения пиримидина в качестве ингибиторов при лечении туберкулеза
NZ724645A (en) Pde10 inhibitors and related compositions and methods
TN2010000299A1 (en) Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydropy-ran-4-yl)-propionamide
MX2013001361A (es) 4-(1h-indol-3-il) - pirimidina como inhibidores de alk.
MX2010008583A (es) Novedosos formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)- 5-ter-butil-pirazol-1-il]benzoico.

Legal Events

Date Code Title Description
FG Grant or registration